Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial Active — Not Recruiting Non-phase study NCT07543575

JIA Toolbox Feasibility Study

JIA Toolbox Feasibility Study — Active Not Recruiting • Non-phase study • Rheumatology • NCT07543575.

📅 22 Apr 2026 ⏱ 2 min read
Active — Not Recruiting
Check the registry for current status and eligibility criteria.
Status
Active — Not Recruiting
Phase
Non-phase study
NCT ID
NCT07543575
Start
2024-05-21
Completion
2026-02-28
ClinicaliQ Trial Snapshot
  • JIA Toolbox Feasibility Study — Active Not Recruiting • Non-phase study • Rheumatology • NCT07543575.
  • Testing three prototype tools to help children with juvenile arthritis manage daily activities more independently and effectively.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

Juvenile Idiopathic Arthritis (JIA) is a long-term rheumatic disease affecting approximately 15,000 children and young people (CYP) in the UK. JIA causes ongoing/long-term joint inflammation, pain, and stiffness, making everyday activities difficult. JIA has been shown to impact physical, social, emotional, and educational development. CYP with JIA find current product aids difficult to use, stigmatising and patronising. This project follows on from a previous successful proof-of-concept study in 2021, involving initial testing on 10 CYP over 9 weeks. These results established that the prototypes addressed an unmet need and worked…

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Axial Spondyloarthritis: Diagnosis and Management (NICE NG65)
Rheumatology · 27 Mar 2026
Refer adults to rheumatology if they present with chronic back pain (≥3 months) plus any of: inflammatory back pain features, elevated inflammatory…
View guideline →
Guideline
Osteoarthritis: Care and Management (NICE CG177)
Rheumatology · 27 Mar 2026
Offer all patients with osteoarthritis structured information about self-management, weight management, and both land-based and aquatic exercise programmes as first-line treatment before…
View guideline →
Guideline
Psoriatic Arthritis: Assessment and Management (NICE NG65)
Rheumatology · 27 Mar 2026
Refer to rheumatology for diagnostic assessment if psoriatic arthritis is suspected in patients with psoriasis and joint symptoms, regardless of psoriasis severity…
View guideline →
Guideline
Gout: Diagnosis and Management (NICE NG219)
Rheumatology · 27 Mar 2026
Diagnose acute gout clinically (sudden joint pain, erythema, swelling) and confirm with serum urate level plus polarising microscopy of synovial fluid showing…
View guideline →
Guideline
2022 EULAR Recommendations for the Management of Rheumatoid Arthritis
Rheumatology · 30 Mar 2026
This EULAR guideline addresses 2022 EULAR Recommendations for the Management of Rheumatoid Arthritis in Rheumatology. Use it to review current recommendation wording,…
View guideline →
Guideline
Rheumatoid Arthritis in Adults: Management (NICE NG100)
Rheumatology · 25 Mar 2026
Start methotrexate within 3 months of persistent synovitis diagnosis, combined with short-term bridging corticosteroids • Adopt treat-to-target strategy aiming for remission or…
View guideline →